Propanc Biopharma reports preclinical data on PRP and TGF-β inhibitor in pancreatic cancer
PPCB•Propanc Biopharma reported that PRP reduced pancreatic ductal adenocarcinoma cell proliferation by 50%, while PRP plus galunisertib reduced it by up to 75%. The company also reported reductions in colony formation and invasion and filed an Australian patent application for the combination.
1. Preclinical findings
Propanc Biopharma reported that PRP reduced cell proliferation by 50% in pancreatic ductal adenocarcinoma cells, while PRP plus galunisertib reduced it by up to 75%. PRP reduced colony formation by up to 59% and invasion by up to 81%; the combination reduced them by up to 68% and 89%, respectively.
2. Patent application
The company said PRP significantly reduced SMAD2, SMAD3 and TGFBR1 transcript levels in the cells. It filed an Australian patent application for the PRP and galunisertib combination.
